Chris Martin (file photo)
ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results
ADC Therapeutics is getting the first pivotal results for the antibody-drug conjugate pipeline that it has spent 8 years and raised $558 million to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
